AU2013202911A1 - Methods and compositions for treating inflammation - Google Patents

Methods and compositions for treating inflammation Download PDF

Info

Publication number
AU2013202911A1
AU2013202911A1 AU2013202911A AU2013202911A AU2013202911A1 AU 2013202911 A1 AU2013202911 A1 AU 2013202911A1 AU 2013202911 A AU2013202911 A AU 2013202911A AU 2013202911 A AU2013202911 A AU 2013202911A AU 2013202911 A1 AU2013202911 A1 AU 2013202911A1
Authority
AU
Australia
Prior art keywords
nanoparticle
antigen
cells
mhc
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013202911A
Other languages
English (en)
Inventor
Pedro Santamaria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Original Assignee
UTI LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP filed Critical UTI LP
Publication of AU2013202911A1 publication Critical patent/AU2013202911A1/en
Priority to AU2016203231A priority Critical patent/AU2016203231B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013202911A 2012-03-26 2013-03-25 Methods and compositions for treating inflammation Abandoned AU2013202911A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016203231A AU2016203231B2 (en) 2012-03-26 2016-05-18 Methods and compositions for treating inflammation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615743P 2012-03-26 2012-03-26
US61/615,743 2012-03-26
PCT/IB2013/052352 WO2013144811A2 (en) 2012-03-26 2013-03-25 Methods and compositions for treating inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016203231A Division AU2016203231B2 (en) 2012-03-26 2016-05-18 Methods and compositions for treating inflammation

Publications (1)

Publication Number Publication Date
AU2013202911A1 true AU2013202911A1 (en) 2013-10-10

Family

ID=48444453

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013202911A Abandoned AU2013202911A1 (en) 2012-03-26 2013-03-25 Methods and compositions for treating inflammation
AU2016203231A Active AU2016203231B2 (en) 2012-03-26 2016-05-18 Methods and compositions for treating inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016203231A Active AU2016203231B2 (en) 2012-03-26 2016-05-18 Methods and compositions for treating inflammation

Country Status (14)

Country Link
US (2) US10988516B2 (enExample)
EP (2) EP2830654B8 (enExample)
JP (3) JP6199955B2 (enExample)
CN (2) CN104321077A (enExample)
AU (2) AU2013202911A1 (enExample)
CA (1) CA2868551C (enExample)
DK (1) DK2830654T3 (enExample)
ES (1) ES2744491T3 (enExample)
IL (2) IL234829B (enExample)
MX (1) MX363000B (enExample)
PL (1) PL2830654T3 (enExample)
PT (1) PT2830654T (enExample)
RU (1) RU2689563C2 (enExample)
WO (1) WO2013144811A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG11201603487YA (en) * 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP3193901B1 (en) * 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
US20160346382A1 (en) * 2015-05-27 2016-12-01 Northwestern University Carbohydrate-modified particles and particulate formulations for modulating an immune response
EP3303635B1 (en) 2015-06-01 2021-09-01 California Institute of Technology Compositions and methods for screening t cells with antigens for specific populations
US12258613B2 (en) 2017-03-08 2025-03-25 California Institute Of Technology Pairing antigen specificity of a T cell with T cell receptor sequences
AU2018248961B2 (en) 2017-04-07 2024-06-20 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases
BE1026147B1 (nl) * 2018-03-29 2019-10-28 Farm@Nutrition Besloten Vennootschap Met Beperkte Aansprakelijkheid Samenstelling voor een voedingsadditief voor dieren en werkwijze om het additief toe te dienen.
CN116790402B (zh) * 2023-01-14 2024-05-14 西北农林科技大学 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
EP4661892A1 (en) * 2023-02-08 2025-12-17 Navigen, Inc. Tnf-alpha binding agents and methods of using the same
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4478946A (en) 1981-07-02 1984-10-23 South African Inventions Development Corporation Carrier bound immunosorbent
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US5171582A (en) 1985-07-31 1992-12-15 Ghent William R Treatment of iodine deficiency diseases
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US4859839A (en) 1988-07-08 1989-08-22 Counter Computer Corporation Point-of-sale terminal for laundry or dry cleaning establishments
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DE69232875T2 (de) 1991-04-23 2003-08-21 Anergen, Inc. MHC-Konjugate zur Verbesserung der Autoimmunität.
US5200189A (en) 1991-07-23 1993-04-06 Ecolab Inc. Peroxyacid antimicrobial composition
CA2130997A1 (en) 1992-02-27 1993-09-02 C. Garrison Fathman Early antigen for autoimmune diabetes
JP2631436B2 (ja) 1992-07-24 1997-07-16 徳厚 小島 排水立て管継手
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
AU2076895A (en) 1994-03-28 1995-10-17 Daiichi Pharmaceutical Co., Ltd. Liposomes
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19508058A1 (de) 1995-02-21 1996-08-22 Schering Ag Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6033864A (en) * 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
DE69730038T2 (de) 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
PT1017721E (pt) 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
CA2321262A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
WO1999056763A1 (en) 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
DE19825371A1 (de) 1998-06-06 1999-12-09 Bayer Ag Elektrochrome Anzeigevorrichtung mit isolierten Zuleitungen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
JP2000213425A (ja) 1999-01-20 2000-08-02 Hino Motors Ltd Ｅｇｒク―ラ
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
CN1377279A (zh) 1999-05-06 2002-10-30 遗传研究所有限公司 可溶性共同刺激分子增强免疫应答的用途
CA2386377A1 (en) 1999-10-06 2001-04-12 The Trustees Of The University Of Pennsylvania Cell targeting compositions and methods of using the same
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
DE10117858A1 (de) 2001-04-10 2002-10-24 Gsf Forschungszentrum Umwelt MHC-Tetramere
US20070129307A1 (en) 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
WO2003001204A2 (en) 2001-06-22 2003-01-03 The University Of British Columbia Type 1 diabetes diagnostics and therapeutics
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
ATE388691T1 (de) 2001-07-10 2008-03-15 Univ North Carolina State Träger zur freisetzung von nanopartikeln
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
DK2224012T3 (da) * 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US6688494B2 (en) 2001-12-20 2004-02-10 Cima Nanotech, Inc. Process for the manufacture of metal nanoparticle
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
JP5068931B2 (ja) 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US6929675B1 (en) 2003-04-24 2005-08-16 Sandia Corporation Synthesis metal nanoparticle
US20050118102A1 (en) 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
EP1628675A4 (en) 2003-05-20 2008-05-07 Univ Virginia ANTIGENS AS A GOAL FOR PREVALENT PATHOGENIC T CELLS IN TYP-1 DIABETES AND USES THEREOF
US7060121B2 (en) 2003-06-25 2006-06-13 Hsing Kuang Lin Method of producing gold nanoparticle
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
WO2005036035A2 (en) 2003-10-09 2005-04-21 Emerson Electric Co. Valve assembly
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
GB0417954D0 (en) 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
WO2006054806A1 (ja) 2004-11-22 2006-05-26 Locomogene, Inc. クローン病関連自己抗原
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070059775A1 (en) 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
US7562421B2 (en) 2005-04-03 2009-07-21 Magen Eco Energy A.C.S. Ltd. Connecting clasp
US7326399B2 (en) 2005-04-15 2008-02-05 Headwaters Technology Innovation, Llc Titanium dioxide nanoparticles and nanoparticle suspensions and methods of making the same
AU2006239154A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc Nanoparticle conjugates
CN101247826A (zh) 2005-08-25 2008-08-20 大鹏药品工业株式会社 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
AU2007283731B2 (en) 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
US7816814B1 (en) 2006-08-18 2010-10-19 Hennessy Michael J Bi-directional power converters
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
MX2009007101A (es) 2006-12-29 2009-12-01 Univ Washington Superficies y materiales antibioincrustación bifuncionales.
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US20150250871A1 (en) 2007-03-07 2015-09-10 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US20140105980A1 (en) 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
CN202189297U (zh) 2007-07-22 2012-04-11 康代有限公司 用于控制电子电路的制造过程的系统
JP5085240B2 (ja) 2007-09-03 2012-11-28 日本電波工業株式会社 水晶デバイス及び水晶デバイスの製造方法
EP2591804A3 (en) 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009064273A1 (en) 2007-11-16 2009-05-22 Paul Appelbaum Apparatus and method for packaging articles in clear plastic packages
US8779088B2 (en) * 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
EP2240782A2 (en) 2008-02-04 2010-10-20 Ulive Enterprises Limited Nanoparticle conjugates
JP2011525477A (ja) 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド 免疫調節剤粒子および処置方法
WO2009126835A2 (en) 2008-04-09 2009-10-15 University Of Washington Techtransfer Invention Licensing Magnetic nanoparticle and method for imaging t cells
US20090258355A1 (en) 2008-04-11 2009-10-15 Brookhaven Science Associates, Llc Nanoscale Clusters and Methods of Making Same
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA2642141A1 (en) 2008-10-20 2010-04-20 Innovative Microelectronics Inc. Flange alignment pin
CA2743590A1 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
SG173041A1 (en) 2009-01-20 2011-08-29 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
US8383085B2 (en) 2009-05-29 2013-02-26 University Of Manitoba Methods of making iron-containing nanoparticles
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
GB201003088D0 (en) 2010-02-24 2010-04-14 Univ Exeter Method for the preparation of a novel nanoparticle conjugate
SG10201604175XA (en) 2010-07-26 2016-07-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
PL2640711T3 (pl) 2010-08-25 2016-06-30 Davuluri Ramamohan Rao Ulepszony sposób otrzymywania rufinamidu
WO2012031258A1 (en) 2010-09-03 2012-03-08 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
CN105497883A (zh) 2010-09-29 2016-04-20 乌第有限合伙公司 使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR101468769B1 (ko) 2011-03-04 2014-12-08 사회복지법인 삼성생명공익재단 갑상선암 특이적 자성나노입자 복합체 및 이의 용도
WO2013034726A1 (en) 2011-09-07 2013-03-14 Midatech Limited Nanoparticle-peptide compositions
EP2758780A4 (en) 2011-09-22 2015-09-16 Marv Entpr Llc METHOD OF TREATING MULTIPLE SCLEROSIS
EP2591801A1 (en) 2011-11-14 2013-05-15 Universitätsklinikum Hamburg-Eppendorf Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions
US20130128138A1 (en) 2011-11-18 2013-05-23 Shenzhen China Star Optoelectronics Technolog Co., LTD. Flat Panel Display Device, Stereoscopic Display Device, Plasma Display Device
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
US8809057B2 (en) 2012-01-04 2014-08-19 Raytheon Bbn Technologies Corp. Methods of evaluating gene expression levels
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150150996A1 (en) 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
EP2986807B1 (en) 2013-08-31 2018-04-04 Halliburton Energy Services, Inc. Deflector assembly for a lateral wellbore
US9335768B2 (en) 2013-09-12 2016-05-10 Lam Research Corporation Cluster mass flow devices and multi-line mass flow devices incorporating the same
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
EP3984542A1 (en) 2014-11-20 2022-04-20 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
KR102825102B1 (ko) 2014-12-24 2025-06-26 넥스이뮨, 인크. 면역요법을 위한 나노입자 조성물 및 방법
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
WO2016145605A1 (zh) 2015-03-17 2016-09-22 王忠堂 一种便携式智能超声多普勒动态实时监测装置
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
JP2020500015A (ja) 2016-11-09 2020-01-09 ユーティーアイ リミテッド パートナーシップ 組換えｐＭＨＣクラスＩＩ分子
AU2018248961B2 (en) 2017-04-07 2024-06-20 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases

Also Published As

Publication number Publication date
JP2018030842A (ja) 2018-03-01
JP2015518467A (ja) 2015-07-02
US20130330414A1 (en) 2013-12-12
EP2830654B1 (en) 2019-07-03
CN104321077A (zh) 2015-01-28
WO2013144811A3 (en) 2013-11-28
WO2013144811A2 (en) 2013-10-03
IL234829A0 (en) 2014-12-31
AU2016203231B2 (en) 2018-02-01
US10988516B2 (en) 2021-04-27
IL234829B (en) 2019-09-26
MX2014011623A (es) 2015-02-12
MX363000B (es) 2019-03-01
PT2830654T (pt) 2019-09-23
US20210230237A1 (en) 2021-07-29
ES2744491T3 (es) 2020-02-25
RU2014141984A (ru) 2016-05-20
JP6570082B2 (ja) 2019-09-04
CN110354278B (zh) 2023-05-02
BR112014023859A2 (pt) 2017-07-18
EP2830654B8 (en) 2019-08-07
DK2830654T3 (da) 2019-08-26
JP2019108399A (ja) 2019-07-04
CA2868551C (en) 2021-07-27
CN110354278A (zh) 2019-10-22
CA2868551A1 (en) 2013-10-03
EP3590531A1 (en) 2020-01-08
JP6199955B2 (ja) 2017-09-20
AU2016203231A1 (en) 2016-06-09
PL2830654T3 (pl) 2020-02-28
US12448419B2 (en) 2025-10-21
RU2689563C2 (ru) 2019-05-28
EP2830654A2 (en) 2015-02-04
BR112014023859A8 (pt) 2018-01-16
IL269166A (en) 2019-11-28
HK1206641A1 (en) 2016-01-15

Similar Documents

Publication Publication Date Title
US12448419B2 (en) Methods and compositions for treating inflammation
JP6899863B2 (ja) 多発性硬化症および関連障害を治療するための方法および組成物
US10905773B2 (en) Methods and compositions for treating multiple sclerosis and related disorders
US20150250871A1 (en) Methods and compositions for treating multiple sclerosis and related disorders
HK40020863A (en) Methods and compositions for treating inflammation
HK1206641B (en) Methods and compositions for treating inflammation
NZ727956A (en) Methods and compositions for treating inflammation
NZ727956B2 (en) Methods and compositions for treating inflammation
HK40009581A (en) Methods and compositions for treating multiple sclerosis and related disorders
BR112014023859B1 (pt) Nanopartícula, uso da mesma, e composição
HK1213912B (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted